CoChat
Sign Up
Cited by 94Adrenal and Paraganglionic TumorsNeuroendocrine Tumor Research AdvancesSarcoma Diagnosis and Treatment

IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours

Open access
Schmitt, A, Saremaslani, P, Schmid, S, Rousson, V, Montani, M, Schmid, D M, Heitz, Ph U, Komminoth, P +1 more·2006·Histopathology
DOI 10.1111/j.1365-2559.2006.02505.x
Open this paper in CoChat — free account

Abstract

AIMS: The differentiation of adrenocortical carcinomas from adenomas may be difficult based on morphology alone. Differential expression of insulin-like growth factor (IGF) II and cyclin-dependent kinase (CDK) 4 has recently been described in these tumours. The aim of this study was to investigate the diagnostic usefulness of these markers immunohistochemically. METHODS AND RESULTS: We examined 22 benign and 17 malignant adrenocortical tumours and compared IGFII and CDK4 expression with known immunohistochemical as well as morphological criteria of malignancy. Thirteen of 17 carcinomas showed immunohistochemical reactivity for IGFII, whereas all adenomas but one were negative. Intense CDK4 expression was detected in 11 of 17 carcinomas but was present in only three of 22 adenomas. The MIB1 index was >5% in 14 of 16 carcinomas and was <5% in all adenomas but one. The combination of IGFII immunohistochemistry with MIB1 index led to high sensitivity and specificity in detecting adrenocortical carcinomas. CONCLUSIONS: IGFII and MIB1 are helpful immunohistochemical markers to predict malignancy in adrenocortical neoplasms. These markers can be used in addition to clinical, gross and morphological features to establish a diagnosis in difficult cases.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2559.2006.02505.x

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The cutoff at which a Ki67 labeling index confirms the diagnosis of ACC and predicts aggressive disease is debated and ranges from >2.5% to >7%.

    “The cutoff at which a Ki67 labeling index confirms the diagnosis of ACC and predicts aggressive disease is debated and ranges from >2.5% to >7% (113,115-117).”

    From Adrenal incidentaloma (2020) · cites this paper as [117]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Schmitt, A., Saremaslani, P., Schmid, S., Rousson, V, Montani, M., Schmid, D. M., Heitz, P. U., Komminoth, P., & Perren, A.
Affiliations
  • University Hospital Zurich (CH)
  • University of Zurich (CH)
Corresponding author
Schmitt, A
ORCID
Venue
Histopathology
Publisher
Wiley
Published
2006-08-18
Volume
49
Issue
3
Pages
298-307
ISSN
  • 0309-0167 (ISSN-L)
  • 1365-2559
DOI
10.1111/j.1365-2559.2006.02505.x
OpenAlex
W1966402276
Cited by
94
References
38
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 5 · 2021: 3 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 10 · 2014: 5 · 2013: 4 · 2012: 4
FWCI
5.78
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Histopathology (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Keywords
adrenocortical carcinoma, adrenal adenoma, CDK4, immunohistochemical markers, benign versus malignant differentiation, adrenocortical tumors, sensitivity and specificity
MeSH terms
Adrenal Cortex Neoplasms, Adult, Aged, Diagnosis, Differential, Golgi Apparatus, Humans, Immunohistochemistry, Middle Aged, Sensitivity and Specificity, Biomarkers, Tumor, Tumor Suppressor Protein p53, Adrenocortical Adenoma, Adrenocortical Carcinoma, Insulin-Like Growth Factor Binding Protein 2, Ki-67 Antigen, Cyclin-Dependent Kinase 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review